The coronavirus pandemic has upended the way the drug industry presents its data.
In recent weeks, many of biopharma’s biggest spring conferences have been cancelled or gone virtual. Two major cancer groups — the American Association for Cancer Research and the American Society of Clinical Oncology —have shifted their massive meetings online.
